AllianceBernstein
CADL icon

AllianceBernstein’s Candel Therapeutics CADL Stock Holding History

AllianceBernstein’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$390K Hold
69,110
– – ﹤0.01% 2762
2025
Q4 		$390K Hold
69,110
– – ﹤0.01% 2781
2025
Q3 		$352K Hold
69,110
– – ﹤0.01% 2865
2025
Q2 		$350K Buy
69,110
+58,450
+548% +$301K ﹤0.01% 2840
2025
Q1 		$60.2K Hold
10,660
– – ﹤0.01% 3114
2024
Q4 		$92.5K Hold
10,660
– – ﹤0.01% 3131
2024
Q3 		$73.9K Hold
10,660
– – ﹤0.01% 3157
2024
Q2 		$66.1K Buy
+10,660
New +$80K ﹤0.01% 3168

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AllianceBernstein's CADL Position: Q1 2026 in Review

AllianceBernstein held its Candel Therapeutics (CADL) position steady in Q1 2026 at 69,110 shares worth $390K. The position accounts for ﹤0.01% of the portfolio, ranked #2762.

AllianceBernstein first reported a position in CADL in Q2 2024 and has held it in 8 quarters since. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • AllianceBernstein held 69,110 shares of Candel Therapeutics worth $390K as of Q1 2026.
  • AllianceBernstein left its Candel Therapeutics share count unchanged in Q1 2026.
  • Candel Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q1 2026, its #2762 holding.
  • AllianceBernstein first reported a position in Candel Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.